Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 54 publications
Incidence, Risk Factors, and Survival Implications of Immune-Related Adverse Events in Patients With Metastatic Breast Cancer.
Journal: Clinical breast cancer
Published: March 20, 2026
UTX coordinates TCF1 and STAT3 to control progenitor CD8+ T cell fate in autoimmune diabetes.
Journal: The Journal of clinical investigation
Published: December 16, 2025
Sex Matters: Hormonal and Chromosomal Determinants of Autoimmunity and Anti-Cancer Immunity Across the Lifespan.
Journal: Immunological reviews
Published: December 11, 2025
Immune Checkpoint Inhibitor-Associated Uveitis: Predictors and Survival Impact.
Journal: Ophthalmology. Retina
Published: October 15, 2025
Safety and clinical outcomes of pembrolizumab standard-interval dosing versus extended-interval dosing in patients with breast cancer.
Journal: The oncologist
Published: August 27, 2025
Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors.
Journal: Journal for immunotherapy of cancer
Published: July 21, 2025
UTX coordinates TCF1 and STAT3 to control progenitor CD8+ T cell fate in autoimmune diabetes.
Journal: The Journal of clinical investigation
Published: June 03, 2025
UTX Coordinates TCF1 and STAT3 to Control Progenitor CD8+ T cell Fate in Autoimmune Diabetes.
Journal: bioRxiv : the preprint server for biology
Published: January 07, 2025
Polyfunctional IL-21+ IFNG+ T follicular helper cells contribute to checkpoint inhibitor diabetes mellitus and can be targeted by JAK inhibitor therapy.
Journal: bioRxiv : the preprint server for biology
Published: December 16, 2024
NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: November 13, 2024
Last Updated: 09/26/2026